pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
Quick answer
George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER2-positive breast carcinoma. NovaPharmaNews links 406 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (187), phase 3 (94), approved (83).
Company snapshot
George Institute for maintains 406 tracked programs across No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER2-positive breast carcinoma, Major depressive disorder, graft-versus-host disease, lumbar arthrodesis, Infertility, acute myeloid leukemia, Hip fracture, Rabies. Momentum score: 20/100 (30-day delta: n/a). Public registry data covers
- 406 active pipeline program(s) linked via ClinicalTrials.gov.
- 406 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for George Institute for. Not investment advice.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for George Institute for.
1 active signal
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for George Institute for.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is George Institute for?
-
Is George Institute for publicly traded?
-
What drugs does George Institute for develop or market?
-
What are the latest developments for George Institute for?
-
What therapeutic areas does George Institute for focus on?
Full intelligence profile
Registry synthesis
Grounded overview from trials, patents, coverage, and catalysts.
George Institute for maintains 406 tracked programs across No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER2-positive breast carcinoma, Major depressive disorder, graft-versus-host disease, lumbar arthrodesis, Infertility, acute myeloid leukemia, Hip fracture, Rabies. Momentum score: 20/100 (30-day delta: n/a).
Public registry data covers pipeline phase, clinical trials, patents, SEC filings, and Nova editorial coverage. HQ: Sydney AU. Ticker: E27A7B8.
Pipeline programs
IB2017-04 — phase phase_3, status active. Indication: Resectable, non-metastatic soft-tissue sarcoma (STS). Next milestone: not disclosed (TBD).
Grafalon 20 mg/ml concentrato per soluzione per infusione — phase phase_3, status active. Indication: To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.. Next milestone: not disclosed (TBD).
6% Hydroxy-ethyl starch (130/0.4) — phase phase_3, status completed. Indication: Intensive Care. Next milestone: not disclosed (TBD).
Skilarence gastro-resistant tablets for Adrenomyeloneuropathy — phase phase_3, status active. Indication: Adrenomyeloneuropathy. Next milestone: not disclosed (TBD).
Vanish Trial — phase phase_3, status active. Indication: People with acute ischemic stroke (AIS) due to large vessel occlusion of the anterior circulation.. Next milestone: not disclosed (TBD).
COBALAMIN — phase phase_3, status active. Indication: Hydroxycobalamin deficiency. Next milestone: not disclosed (TBD).
IIBSP-IPV-2024-178 — phase phase_3, status active. Indication: lumbar arthrodesis. Next milestone: not disclosed (TBD).
Colchicine 0.5 mg — phase phase_3, status active. Indication: Intracerebral Hemorrhage. Next milestone: not disclosed (TBD).
2023/3720 UMBRELLA — phase phase_3, status active. Indication: patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment. Next milestone: not disclosed (TBD).
2023/3764 — phase phase_3, status active. Indication: Metastatic renal cell carcinoma (mRCC). Next milestone: not disclosed (TBD).
PROICM 2021-01 GRE — phase phase_3, status active. Indication: Rectum cancer. Next milestone: not disclosed (TBD).
REACT — phase phase_3, status active. Indication: Community-acquired pneumonia. Next milestone: not disclosed (TBD).
Recent Nova coverage
No linked Nova articles yet.
Registry facts
Registry profile: founded 1999; employees 841; market cap n/a; revenue n/a; LEI 335800STO5VFCNJDJR15; CIK n/a.
Company type: pharma; public/private: public. Data quality score: 0.800.
Catalyst calendar
No dated catalysts in window.
Competitive peers
Peer: NORTHWEST BIOTHERAPEUTICS (overlap score 26.6).
Peer: Peking University Biologics (overlap score 23.0).
Competitive positioning reflects therapeutic-area overlap with peer sponsors and recent catalyst activity from trials, regulatory actions, and congress presentations. Data is assembled from ClinicalTrials.gov, SEC EDGAR, openFDA, and NovaPharmaNews articles — not third-party wire republication.
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.